Locally Advanced Oral Tongue Cancer: Is Organ Preservation a Safe Option in Resource-Limited High-Volume Setting?
High-volume center
induction chemotherapy
oral tongue
organ preservation
survival outcome
Journal
Annals of maxillofacial surgery
ISSN: 2231-0746
Titre abrégé: Ann Maxillofac Surg
Pays: India
ID NLM: 101598423
Informations de publication
Date de publication:
Historique:
received:
24
07
2019
revised:
17
12
2019
accepted:
31
01
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
29
8
2020
Statut:
ppublish
Résumé
Oral tongue is found to be the most common intraoral subsite with worse prognosis despite the use of multimodality treatments. Extensive resections have resulted in loss of form and function of tongue in advanced tumors. The objective of the study was to analyze the role of induction chemotherapy (IC) in intermediate to advanced staged oral tongue cancer for organ preservation and survival outcome in a developing country. The records of oral tongue cancer patients treated from 2007 to 2016 were retrospectively analyzed. Eighty-one oral tongue cancer patients with advanced stage were treated using induction arm in 10 years. The median follow-up was 24 months with 3- and 5-year survival of 77% and 58%, respectively. IC has an overall response in 87% of the patients at primary site. The chemotherapy has completely resolved the nodal disease in 17% of the patients, but 23% of the patients had failed to respond. Only 21% of the patients received reconstruction using local or regional flaps. IC has shown encouraging results in advanced staged oral tongue cancers with function preservation and improved survival outcome in less privileged high-volume centers.
Sections du résumé
BACKGROUND
BACKGROUND
Oral tongue is found to be the most common intraoral subsite with worse prognosis despite the use of multimodality treatments. Extensive resections have resulted in loss of form and function of tongue in advanced tumors. The objective of the study was to analyze the role of induction chemotherapy (IC) in intermediate to advanced staged oral tongue cancer for organ preservation and survival outcome in a developing country.
MATERIALS AND METHODS
METHODS
The records of oral tongue cancer patients treated from 2007 to 2016 were retrospectively analyzed.
RESULTS
RESULTS
Eighty-one oral tongue cancer patients with advanced stage were treated using induction arm in 10 years. The median follow-up was 24 months with 3- and 5-year survival of 77% and 58%, respectively. IC has an overall response in 87% of the patients at primary site. The chemotherapy has completely resolved the nodal disease in 17% of the patients, but 23% of the patients had failed to respond. Only 21% of the patients received reconstruction using local or regional flaps.
CONCLUSION
CONCLUSIONS
IC has shown encouraging results in advanced staged oral tongue cancers with function preservation and improved survival outcome in less privileged high-volume centers.
Identifiants
pubmed: 32855933
doi: 10.4103/ams.ams_166_19
pii: AMS-10-158
pmc: PMC7433937
doi:
Types de publication
Journal Article
Langues
eng
Pagination
158-163Informations de copyright
Copyright: © 2020 Annals of Maxillofacial Surgery.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Oral Oncol. 2012 Nov;48(11):1076-84
pubmed: 22800881
World J Surg Oncol. 2013 Mar 14;11:67
pubmed: 23497185
Sci Rep. 2015 Jun 04;5:10798
pubmed: 26041604
J Clin Oncol. 2013 Aug 10;31(23):2854-60
pubmed: 23835714
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Dysphagia. 2006 Apr;21(2):102-11
pubmed: 16685469
Cancer Res Treat. 2016 Jul;48(3):907-16
pubmed: 26582394
Cancer Treat Rev. 2015 Mar;41(3):217-21
pubmed: 25687982
Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):28-32
pubmed: 14732764
Springerplus. 2015 May 01;4:208
pubmed: 25977896
Am J Clin Oncol. 2001 Dec;24(6):618-22
pubmed: 11801767
Radiother Oncol. 2008 Oct;89(1):44-50
pubmed: 18423671
Oral Oncol. 2019 Aug;95:164-169
pubmed: 31345386
Oral Oncol. 2013 Jun;49(6):507-24
pubmed: 23566773
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD006386
pubmed: 20824847
Cancer J. 2017 Mar/Apr;23(2):79-83
pubmed: 28410291
Radiother Oncol. 2011 Jul;100(1):33-40
pubmed: 21684027
Eur J Cancer. 2015 Nov;51(17):2596-603
pubmed: 26318725
Cancer Treat Rev. 2016 Mar;44:10-6
pubmed: 26924194
JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699
pubmed: 28426848
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
pubmed: 17237035
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902